Cost-effectiveness of novel regimens for the treatment of hepatitis C virus

Annals of Internal Medicine

Volumn 162, Issue 6, 2015, Pages 407-419

  Najafzadeh, Mehdi ^a   Andersson, Karin ^b   Shrank, William H ^c   Krumme, Alexis A ^a   Matlin, Olga S ^c   Brennan, Troyen ^c   Avorn, Jerry ^a   Choudhry, Niteesh K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c CVS Caremark   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; DACLATASVIR; LEDIPASVIR PLUS SOFOSBUVIR; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; BMS-790052; FLUORENE DERIVATIVE; FUSED HETEROCYCLIC RINGS; IMIDAZOLE DERIVATIVE; LEDIPASVIR, SOFOSBUVIR DRUG COMBINATION; SULFONAMIDE; URIDINE PHOSPHATE;

ADULT; AGED; ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; MALE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; ANALOGS AND DERIVATIVES; BIOLOGICAL MODEL; COST BENEFIT ANALYSIS; DISEASE COURSE; DRUG COMBINATION; ECONOMICS; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; SENSITIVITY AND SPECIFICITY;

ANTIVIRAL AGENTS; BENZIMIDAZOLES; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG COSTS; DRUG THERAPY, COMBINATION; FLUORENES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; IMIDAZOLES; INTERFERON-ALPHA; PATIENT-SPECIFIC MODELING; RIBAVIRIN; SENSITIVITY AND SPECIFICITY; SULFONAMIDES; URIDINE MONOPHOSPHATE;

EID: 84924862927     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M14-1152     Document Type: Article

References (53)

1. Yee HS, Chang MF, Pocha C, Lim J, Ross D, Morgan TR, et al; Department of Veterans Affairs Hepatitis C Resource Center Program. Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol. 2012;107:669-89. [PMID: 22525303] doi:10.1038/ajg.2012.48
2. U.S. Food and Drug Administration approves Gilead's Sovaldi (sofosbuvir) for the treatment of chronic hepatitis C [press release]. Foster City, CA: Gilead Sciences; 6 December 2013.
3. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878-87. [PMID: 23607594] doi:10.1056/NEJMoa1214853
4. Osinusi A, Meissner EG, Lee YJ, Bon D, Heytens L, Nelson A, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA. 2013;310:804-11. [PMID: 23982366] doi:10.1001/jama.2013.109309
5. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, et al; VALENCE Investigators. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370:1993-2001. [PMID: 24795201] doi:10.1056/NEJMoa1316145
6. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al; POSITRON Study. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368:1867-77. [PMID: 23607593] doi:10.1056 /NEJMoa1214854
7. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384:1756-65. [PMID: 25078309] doi:10.1016/S0140-6736(14)61036-9
8. Jacobson I, Ghalib R, Rodriguez-Torres Mea. SVR results of a once-daily regimen of simeprevir (SMV, TMC435) plus sofosbuvir (SOF, GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: the COSMOS study [Abstract]. Presented at 64th Annual Meeting of the American Association for the Study of Liver Diseases, Washington, DC, 1-5 November 2013. Abstract no. LB3.
9. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al; AI444040 Study Group. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211-21. [PMID: 24428467] doi:10.1056 /NEJMoa1306218
10. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al; ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889-98. [PMID: 24725239] doi:10.1056/NEJMoa1402454
11. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al; ION-3 Investigators. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370: 1879-88. [PMID: 24720702] doi:10.1056/NEJMoa1402355
12. Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383:515-23. [PMID: 24209977] doi:10.1016/S0140-6736(13)62121-2
13. Gilead announces phase 2 results for two investigational all-oral sofosbuvir-based regimens for the treatment of chronic hepatitis C [press release]. London: Gilead Sciences; 10 April 2014.
14. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705-14. [PMID: 16702586]
15. Brennan T, Shrank W. New expensive treatments for hepatitis C infection. JAMA. 2014;312:593-4. [PMID: 25038617] doi:10.1001 /jama.2014.8897
16. Owens GM. Hepatitis C: new treatments emerge in 2014 that will have profound implications for payers. Am J Manag Care. 31 March 2014. Accessed at www.ajmc.com/payer-perspectives/0314 /-Hepatitis-C-New-Treatments-Emerge-in-2014-That-Will-Have-Profound-Implications-for-Payers on 23 January 2015.
17. Caro JJ, Briggs AH, Siebert U, Kuntz KM; ISPOR-SMDM Modeling Good Research Practices Task Force. Modeling good research practices-overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Med Decis Making. 2012;32:667-77. [PMID: 22990082]
18. Caro JJ, Mö ller J, Getsios D. Discrete event simulation: the preferred technique for health economic evaluations? Value Health. 2010;13:1056-60. [PMID: 20825626] doi:10.1111/j.1524-4733 .2010.00775.x
19. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York: Oxford Univ Pr; 1996.
20. Karnon J, Stahl J, Brennan A, Caro JJ, Mar J, Mö ller J. Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4. Med Decis Making. 2012;32:701-11. [PMID: 22990085]
21. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364: 1195-206. [PMID: 21449783] doi:10.1056/NEJMoa1010494
22. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonc cales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-82. [PMID: 12324553]
23. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368:34-44. [PMID: 23281974] doi:10.1056/NEJMoa1208953
24. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139:120-9. [PMID: 20399780] doi:10.1053/j.gastro.2010.04.013
25. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al; IDEAL Study Team. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580-93. [PMID: 19625712] doi:10.1056/NEJMoa0808010
26. Holmes JA, Desmond PV, Thompson AJ. Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection? J Viral Hepat. 2012;19:677-84. [PMID: 22967098] doi:10.1111/jvh.12003
27. Anand BS, Currie S, Dieperink E, Bini EJ, Shen H, Ho SB, et al; VA-HCV-001 Study Group. Alcohol use and treatment of hepatitis C virus: results of a national multicenter study. Gastroenterology. 2006; 130:1607-16. [PMID: 16697724]
28. Russell M, Pauly MP, Moore CD, Chia C, Dorrell J, Cunanan RJ, et al. The impact of lifetime alcohol use on hepatitis C treatment outcomes in privately insured members of an integrated health care plan. Hepatology. 2012;56:1223-30. [PMID: 22488513] doi:10.1002 /hep.25755
29. Denniston MM, Jiles RB, Drobeniuc J, Klevens RM, Ward JW, McQuillan GM, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 2014;160:293-300. [PMID: 24737271] doi: 10.7326/M13-1133
30. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825-32. [PMID: 9121257]
31. Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology. 2001;34:809-16. [PMID: 11584380]
32. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008;48:418-31. [PMID: 18563841] doi:10.1002/hep.22375
33. Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med. 2012;156:279-90. [PMID: 22351713] doi:10.7326/0003-4819-156-4-201202210-00005
34. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Empirically calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol. 2002;156:761-73. [PMID: 12370165]
35. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Costeffectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA. 2003;290:228-37. [PMID: 12851278]
36. Arias E. National Vital Statistics Reports. Vol. 61. No. 3. Hyattsville, MD: U.S. Department of Health and Human Services; 2012.
37. Sullivan PW, Ghushchyan V. Preference-Based EQ-5D index scores for chronic conditions in the United States. Med Decis Making. 2006;26:410-20. [PMID: 16855129]
38. McLernon DJ, Dillon J, Donnan PT. Health-state utilities in liver disease: a systematic review. Med Decis Making. 2008;28:582-92. [PMID: 18424560] doi:10.1177/0272989X08315240
39. McAdam-Marx C, McGarry LJ, Hane CA, Biskupiak J, Deniz B, Brixner DI. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm. 2011;17:531-46. [PMID: 21870894]
40. McCombs JS, Yuan Y, Shin J, Saab S. Economic burden associated with patients diagnosed with hepatitis C. Clin Ther. 2011;33: 1268-80. [PMID: 21840056] doi:10.1016/j.clinthera.2011.07.008
41. Ryan B. FDA approves Gilead's hep C drug Harvoni (ledipasvir/ sofosbuvir). Hep Magazine. 10 October 2014.
42. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289-93. [PMID: 8690394]
43. Brown RS. Hepatitis C and liver transplantation. Nature. 2005; 436:973-8. [PMID: 16107838]
44. Davis KL, Mitra D, Medjedovic J, Beam C, Rustgi V. Direct economic burden of chronic hepatitis C virus in a United States managed care population. J Clin Gastroenterol. 2011;45:e17-24. [PMID: 20628308] doi:10.1097/MCG.0b013e3181e12c09
45. Gordon SC, Pockros PJ, Terrault NA, Hoop RS, Buikema A, Nerenz D, et al. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. Hepatology. 2012;56:1651-60. [PMID: 22610658] doi:10.1002/hep.25842
46. Solomon M, Bonafede M, Pan K, Wilson K, Beam C, Chakravarti P, et al. Direct medical care costs among pegylated interferon plus ribavirin-treated and untreated chronic hepatitis C patients. Dig Dis Sci. 2011;56:3024-31. [PMID: 21717127] doi:10.1007/s10620-011-1802-z
47. Chan K, Lai MN, Groessl EJ, Hanchate AD, Wong JB, Clark JA, et al. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the Veterans Health Administration. Clin Gastroenterol Hepatol. 2013;11:1503-10. [PMID: 23707354] doi:10.1016/j.cgh.2013.05.014
48. Ferrante SA, Chhatwal J, Brass CA, El Khoury AC, Poordad F, Bronowicki JP, et al. Boceprevir for previously untreated patients with chronic hepatitis C genotype 1 infection: a US-based costeffectiveness modeling study. BMC Infect Dis. 2013;13:190. [PMID: 23621902] doi:10.1186/1471-2334-13-190
49. CPI inflation calculator. Bureau of Labor Statistics. 2014. Accessed at www.bls.gov/data/inflation-calculator.htm on 24 January 2015.
50. Claxton K, Sculpher M, McCabe C, Briggs A, Akehurst R, Buxton M, et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ. 2005;14:339-47. [PMID: 15736142]
51. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000;17:479-500. [PMID: 10977389]
52. Spiegelhalter DJ, Best NG. Bayesian approaches to multiple sources of evidence and uncertainty in complex cost-effectiveness modelling. Stat Med. 2003;22:3687-709. [PMID: 14652869]
53. FDA approves Viekira Pak to treat hepatitis C [press release]. Silver Spring, MD: U.S. Food and Drug Administration; 19 December 2014. Accessed at www.fda.gov/NewsEvents/Newsroom/Press Announcements/ucm427530.htm on 22 December 2014.